To Screen or Not to Screen, That is the Question

“today’s cancer screenings can unearth tumors that scientists say never would have threatened the person’s life. The problem is that there aren’t surefire ways to tell in advance which tumors won’t be dangerous.” Adds Dr. Len Lichtenfeld, Deputy Chief Medical Officer at the American Cancer Society, “We’re really at a tipping point right now where we have a trade-off between the benefits of finding cancer early and the harms that are caused. We treat more patients than we know will benefit, we just don’t know who they are.”

Well that’s just great. What is a consumer to do? As usual, the answer is, “good question.”

This whole area is particularly contentious in light of the effort underway to reduce the cost of healthcare overall. Whenever the debate about cancer screening arises, particularly when it comes down on the side of “less is more,” both providers and consumers get pretty freaked out. Remember last year when the U.S. Preventive Services Task Force recommended ending mammograms for women between 40 and 50 because those mammograms were deemed to be largely ineffective in screening for cancer and had significant negative side effects? Who would have thought that millions of women would rise up and demand the right to stick their breasts into what feels like a waffle iron if solid scientific evidence suggests that it may not be helpful?

Any attempt to limit cancer screening is generally met with the assumption that there is a vast conspiracy to withhold care to reduce costs. Even if that is true, and it probably is when you get right down to it, the intent isn’t always sinister. Tightening up the screening rules may also have some significant advantages to consumers. The big challenge lies in the lack of consensus, even among medical experts, about when screening is necessary and when the negative side effects (such as false positives and the resulting unnecessary additional diagnostic and treatment interventions) outweigh the benefits. In the debate over the appropriateness of mammograms for breasts that have yet to feel the effects of gravity, the American Cancer Society and the American College of Radiology pit themselves against the American College of Physicians and the National Women’s Health Network. If you’re the patient, how do you know where to cast your vote?

This area of medicine, like so many others, sits squarely in the environs of art vs. science. What the powers that be end up telling you is, “ask your doctor.” And yet, what if your doctor just doesn’t know the right answer? If they are advocates of both the American Cancer Society and the National Women’s Health Network, which team jacket are they going to wear?

One area that seems to be an obvious place to eliminate screening tests is among those people who clearly do not need them at all. For instance, government guidelines suggest that men over 75 shouldn’t bother with PSA tests, themselves controversial even for younger men. However, about 1/3 of men over age 75 do get PSA tests, despite the fact that these men rarely die from prostate cancer. A 2004 study found that nearly 10 million women had received Pap smears (the screen for cervical cancer) despite having had total hysterectomies (including removal of the cervix) for noncancerous reasons. Ok, that’s just lame. And it’s what leads to the charge that

Author: Lisa Suennen

Lisa Suennen is a managing director with GE Ventures and former managing member of the Psilos Group, as well as the co-author of Tech Tonics: Can Passionate Entrepreneurs Heal Healthcare With Technology? and author of the blog Venture Valkyrie. Prior to 2014, Lisa was a Senior Advisor to Psilos Group, a healthcare-focused venture capital and growth equity firm that focuses on the healthcare information technology, healthcare services and medical device sectors. Lisa was a co-founder of Psilos Group and a Partner at the firm from 1998-2014. Prior to Psilos, Lisa was at Merit Behavioral Care (formerly American Biodyne, Inc), an $800mm behavioral healthcare company where she held various senior executive roles from its early start-up days through exit. Previously, Lisa held various positions in marketing and product management in companies in the high technology field. Lisa was a Board Member of the Dignity Health Foundation, and Board Member of health IT company Beyond Lucid Technologies and is still a Board Member of medical device company AngioScore, a member of the Qualcomm Life Advisory Board, and an Advisor to the California Health Care Foundation Innovation Fund. Lisa also previously served as an Advisor to innovation consulting firm Accelevate, Inc. as a member of the Advisory Board of the U.S. Health and Human Services Office of the National Coordinator Investing in Innovations program. Lisa holds an M.A. in political science, a B.A. in political science and a B.A. in mass communications, all from the University of California, Berkeley, where she is now Vice Chair of the National Advisory Council of the Institute of Governmental Studies at the University. Lisa is also a visiting lecturer at the U.C. Berkeley Haas School of Business where she teaches the annual course on healthcare venture capital. Lisa also writes a widely read blog on healthcare and healthcare investing at www.venturevalkyrie.com. She has recently published her first book, entitled: Tech Tonics, Can Passionate Entrepreneurs Heal Healthcare with Technology, coauthored with Dr. David Shaywitz.